Unknown

Dataset Information

0

A Novel Histone Deacetylase Inhibitor, AR-42, Reactivates HIV-1 from Chronically and Latently Infected CD4+ T-cells.


ABSTRACT: Human immunodeficiency virus type 1 (HIV-1) latency is a major barrier to a cure of AIDS. Latently infected cells harbor an integrated HIV-1 genome but are not actively producing HIV-1. Histone deacetylase (HDAC) inhibitors, such as vorinostat (SAHA), have been shown to reactivate latent HIV-1. AR-42, a modified HDAC inhibitor, has demonstrated efficacy against malignant melanoma, meningioma, and acute myeloid leukemia and is currently used in clinical trials for non-Hodgkin's lymphoma and multiple myeloma. In this study, we evaluated the ability of AR-42 to reactivate HIV-1 in the two established CD4+ T-cell line models of HIV-1 latency. In HIV-1 chronically infected ACH-2 cells, AR-42-induced histone acetylation was more potent and robust than that of vorinostat. Although AR-42 and vorinostat were equipotent in their ability to reactivate HIV-1, AR-42-induced maximal HIV-1 reactivation was twofold greater than vorinostat in ACH-2 and J-Lat (clone 9.2) cells. These data provide rationale for assessing the efficacy of AR-42-mediated HIV-1 reactivation within primary CD4+ T-cells.

SUBMITTER: Mates JM 

PROVIDER: S-EPMC4739806 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature

altmetric image

Publications

A Novel Histone Deacetylase Inhibitor, AR-42, Reactivates HIV-1 from Chronically and Latently Infected CD4<sup>+</sup> T-cells.

Mates Jessica M JM   de Silva Suresh S   Lustberg Mark M   Van Deusen Kelsey K   Baiocchi Robert A RA   Wu Li L   Kwiek Jesse J JJ  

Retrovirology : research and treatment 20151015


Human immunodeficiency virus type 1 (HIV-1) latency is a major barrier to a cure of AIDS. Latently infected cells harbor an integrated HIV-1 genome but are not actively producing HIV-1. Histone deacetylase (HDAC) inhibitors, such as vorinostat (SAHA), have been shown to reactivate latent HIV-1. AR-42, a modified HDAC inhibitor, has demonstrated efficacy against malignant melanoma, meningioma, and acute myeloid leukemia and is currently used in clinical trials for non-Hodgkin's lymphoma and multi  ...[more]

Similar Datasets

| S-EPMC8463797 | biostudies-literature
| S-EPMC9243624 | biostudies-literature
| S-EPMC6280990 | biostudies-literature
| S-EPMC2798357 | biostudies-literature
| S-EPMC8639145 | biostudies-literature
| S-EPMC6541658 | biostudies-literature
| S-EPMC5567660 | biostudies-literature
| S-EPMC2945885 | biostudies-literature
| S-EPMC5256597 | biostudies-literature
| S-EPMC4079759 | biostudies-literature